According to an analysis from an all-payer-all-claims database, nearly 700,000 Americans aged 30 and under have been diagnosed with gender dysphoria in the last five years, with 300,000 individuals under the age of 18.
In this session, we will provide an in-depth exploration of the rapidly evolving field of gender-affirming care, with a focus on risk management and cost implications. Panelists will discuss the prevalence of gender dysphoria in the U.S., highlighting the significant increase in diagnoses among adolescents. Attendees will learn about the treatment protocols endorsed by the World Professional Association for Transgender Health (WPATH) and examine the contrasting approaches adopted by several European countries, which have revised their guidelines in response to systematic reviews showing limited psychological benefits and unforeseen risks associated with medical transition pathways.
In this session, we will address the implications of these international shifts for U.S. practices, including the recent regulatory changes-such as Tricare's cessation of medical transition for minors and restrictions passed in 26 states. With the anticipated policy changes under the new administration, attendees will gain insights to help insurance companies navigate uncertainty and manage the associated multi-faceted risks.
Learning Outcomes:
Understanding the prevalence and trends in gender dysphoria diagnoses, medical transition, and discontinuation of treatment (medical detransition) in the U.S.
Analysis of recent scientific evidence prompting revisions to treatment protocols for minors - Discussion of unique risks, uncertainties, and long-term implications of gender transition and detransition.
Identifying risk mitigation strategies given the rapidly evolving medical practice and the significant regulatory uncertainties at the state and federal level.